Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ionis Sells Kynamro To Kastle After Regaining Rights From Genzyme

Executive Summary

Three and a half months after Ionis Pharmaceuticals Inc. surprised investors with the news that Sanofi's Genzyme business unit would no longer market Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH), the Carlsbad, California-based biotechnology company revealed that it sold global rights to the cholesterol-lowering drug to Kastle Therapeutics LLC for up to $95m.


Related Content

Ionis: Another Shot At The Commercial Market And Sustainable Profits
Biogen/Ionis’ Spinraza Data Shows Opportunity For Broad SMA Label
Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha
JPM: Ionis Looks Past Kynamro To Profitability
Repatha OK'd; Payers Eye PCSK9 Rebate/Discount War
Dislipidemia market to slump 60% as cheap statins undercut new drugs
A win for antisense: Isis/Genzyme score US OK for Kynamro
No HoFH definition could give Aegerion market lead with Juxtapid


Related Companies